Results pending
Corticosteroids (relapse treatment): reduce relapses and new lesions in secondary progressive MS
secondary progressive MS · Corticosteroids (relapse treatment)
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 3
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 3
These linked trials do not set the status.
- EFFRITENo result found
Phase 2 · 2018 · Compared with rituximab
- COMTiMSResult in a paper, not read yet
Phase 2 · 2011 · Not randomised
- EPO-ProgMSNo result found
Phase 2 · 2009 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 1 → 3
- 2026-10-28Status changed from No clear answer to Results pending
- 2026-10-27First listed as No clear answer
Related hypotheses
- Corticosteroids (relapse treatment): prevent attacks in NMOSD
- Corticosteroids (relapse treatment): reduce relapses and new lesions in optic neuritis
- Corticosteroids (relapse treatment): reduce relapses and new lesions in primary progressive MS
- Corticosteroids (relapse treatment): reduce relapses and new lesions in relapsing MS
- Corticosteroids (relapse treatment): reduce relapses and new lesions in relapsing and progressive MS
- Corticosteroids (relapse treatment): reduce relapses and new lesions in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error